Business
Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day
Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and Support Clinical Trial Design Announced for SEQUOIA-HCM, Phase 3 Clinical Trial of Aficamten Expected to Begin in Q4 Company Details Plan for Developing a Cardiovascular Franchise SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) plans to outline the company’s go-to-market strategy for omecamtiv mecarbil in the United States, and present updates on the company’s advancing cardiovascular pipeline and strategies to build a commercial franchise at “Charting the Commercial Course,” an Analyst and Investor Day today at 8:30 AM Eastern Time in New York and live online. The company also plans to present the clinical trial design for SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). “Cytokinetics is approaching an inflection point after more than two decades of research and development pioneering the field of muscle biology and advancing the pharmacology of myosin modulators. With new key leadership hires and our establishing of strategic commercial capabilities, we are putting in place the architecture for the potential launch of omecamtiv mecarbil in 2022, staging investments with de-risking milestone events and with deliberate focus to building a framework for a potential cardiovascular business franchise as could be enabled by the subsequent launch of aficamten,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “As aficamten advances into Phase 3 with SEQUOIA-HCM, expected to begin this year, our company is well positioned to deliver on the promise of potential medicines for patients with cardiovascular diseases of impaired muscle function and weakness.” Go-To-Market Strategy for Omecamtiv Mecarbil Cytokinetics leadership will outline the go-to-market strategy for omecamtiv mecarbil in the U.S., which will be guided by a sequenced build of core capabilities to ensure success based on key de-risking milestones leading up to the potential launch of omecamtiv mecarbil. The four pillars of the strategy include first, establishing a deep understanding of patients with worsening heart failure and the healthcare providers and associated insti...